Moderators: Celeste Abjornson, PhD; Jack E. Zigler, MD
Over the past 15 years, there have been numerous Level 1 clinical trials and robust debate to establish total disc replacements (TDRs) in the care continuum of degenerative disc disease (DDD). However, TDR has not overtaken fusion as the treatment decision as originally anticipated. The Triple R's--Regulatory, Results and Reimbursement--have dominated the discussion but what progress has been achieved? Faculty will present a value-based analysis of TDR compared to fusion alternatives over the decade following surgery, discuss the best clinical outcomes to measure long-term sustainability of the surgical options, and review the reimbursement landscape and coding updates.
Upon completion of this session, participants will gain strategies to:
- Discuss the value analysis of the surgical options;
- Review the clinical evidence, related complications and postoperative pathway;
- Focus on the clinical data analysis: Are we utilizing the right outcome measures or just applying the same old ones? How do we measure success?;
- Present the current changes to reimbursement and coding for cervical and lumbar disc replacements.
Agenda
Introduction: What Were We Afraid Of?
Jack Zigler, MD
Timeline of Cervical and Lumbar Total Disc Replacement 2000 to Present
Thierry Marnay, MD
Cervical TDR - Indications and Outcomes
Rick Guyer, MD
Lumbar TDR - Indications and Outcomes
Scott Blumenthal, MD
Reimbursement and Coding: Is it Getting Better?
Kimberly Norton
What's on the Horizon?
Pierce Nunley, MD
Health Economics: Does Arthroplasty Make Economic Sense?>
Jack Zigler, MD
Discussion, Questions and Answers
Faculty Panel